Skip to content

Beetroot Juice NO Cold Study

Beetroot Juice Supplement for Boosting Mucosal Immunity - The NO Cold Study

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06416228
Acronym
NCS
Enrollment
150
Registered
2024-05-16
Start date
2024-04-02
Completion date
2026-05-15
Last updated
2024-05-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cold Symptoms, Exhaled Nitric Oxide, Respiratory Tract Infections

Brief summary

Currently, there is a lack of evidence-based prevention strategies for respiratory infection and management of these conditions can be costly to the public. Airway nitric oxide provides a first line of defense against pathogens, and beetroot juice, a source of dietary nitrate, has been shown to elevate nitric oxide. The main objective of this project is to demonstrate that one week of supplementation with beetroot juice elevates airway nitric oxide during stressful periods in young adults and thereby can protect against respiratory viral infections.

Detailed description

Study Title Beetroot Juice Supplement for Boosting Mucosal Immunity: The NO Cold Study Objectives Aim 1: Demonstrate that a 7-day trial of daily beetroot juice or nitrate depleted placebo beetroot juice is feasible with acceptable retention and adherence during a period of real-life stress, using adherence monitoring of beetroot juice intake by cell phone recorded video; acceptable burdensomeness for participants and success of team coordination and study logistics should also be demonstrated. Aim 2: Generate initial estimates of effect size for a) elevations in exhaled nitric oxide (FENO) and b) the correlation between changes in FENO and both infection reduction and cold symptom reduction (biological signature). Aim 3: a) Examine if 2 daily doses of beetroot juice are more potent than 1 daily dose in elevating FENO, and b) investigate whether each beetroot juice dosage (1 dose and 2 doses) increases FENO more than the placebo. Exploratory aims: Explore sex as a moderator of all the Aims. Also explore effects of competitors/inhibitors of NO (arginase, asymmetric dimethylarginine) in a) reducing FENO under stress, and b) whether beetroot juice buffers any of these potential adverse effects on FENO; c) investigate whether effects of stress cortisol, which negatively impact NO, cold symptoms, and respiratory infections, are also buffered by beetroot juice. Design and Outcomes This is a double-blind, placebo controlled clinical trial to test the efficacy of beetroot juice as elevating airway NO, which is associated with reduced cold symptoms and respiratory viral infection rates, in undergraduate students aged 18-30. Interventions and Duration Participants will be receiving 1 active daily dose of beetroot juice and 1 dose of nitrate-depleted placebo beetroot juice, 2 active daily doses of beetroot juice, or 2 daily doses of nitrate-depleted placebo beetroot. Cold symptoms will be explored by questionnaire at baseline (in a low stress period during the semester) and subsequently twice during the final exam period, once at an early stage of the finals (days 1-3 of the final exam period), and once at a later stage (days 4-6). A follow-up online questionnaire packet will be administered 3 days after the last final day. FENO, sampling for viral PCR, salivary cortisol, and exhaled breath condensate will be undertaken at baseline, early finals, and late finals (in-person assessments are not feasible at follow-up, because students leave campus after finals). Sample Size and Population The sample size is 150 students (n=66 at SMU site, n=84 at Baylor site). Female and male students 18-30 years old will be recruited from Baylor and SMU. The investigators will make an extra effort to guarantee equal representation of both genders. Participants can be from any ethnic or cultural background, as long as they can understand and read English adequately. The student population of both universities combined is diverse (28.5-38.5% minorities). The investigators will stratify by sex and by site, to randomize participants to receiving 1 active daily dose of beetroot juice and 1 dose of nitrate-depleted placebo beetroot juice, 2 active daily doses of beetroot juice, or 2 daily doses of nitrate-depleted placebo beetroot juice (n=50 per group).

Interventions

DIETARY_SUPPLEMENTBeetroot juice

Participants will take on dose in the morning and one in the afternoon, for 7 days during their final academic examinations

Sponsors

Baylor University
CollaboratorOTHER
Southern Methodist University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Masking description

Both participating students and assessors will be blinded to the participants' group assignment. Since students and research staff will not know whether their beetroot juice is depleted or not, treatment conditions are double-blinded (juice shots will be pre-labeled by study statistician with a participant number based on the pre-study randomization, so neither the staff nor the participant know the contents). Students will also be assured of full blinding of course instructors, including the PIs and Co-Is, to names of study participants.

Intervention model description

Double blinded, placebo controlled study

Eligibility

Sex/Gender
ALL
Age
18 Years to 30 Years
Healthy volunteers
Yes

Inclusion criteria

Individuals will be included: * SMU or Baylor University students * Ages of 18-30 years old.

Exclusion criteria

* Active smokers * Smoking cannabis or vape * Students with clinically significant asthma * COPD and emphysema * Allergic rhinitis * High levels of exhaled nitric oxide (FENO ≥40ppb) * Developing kidney stone * Clinically significant heart disease * Cerebrovascular disease * Thyroid dysfunction * Out-of-control diabetes * Significant current problems with schizophrenia, psychosis, mood disorders, suicidality, and drug or alcohol dependence or abuse

Design outcomes

Primary

MeasureTime frameDescription
Burdensomeness1-3 days after finishing beetroot shots (after final examinations)Follow-up questionnaire will be administered with the online follow-up survey. It explores experience with the best mode of reminder receipt (email or text message), whether the participants guessed their condition, and how burdensome 8 aspects of the study (including daily intake, video recording, upload, questionnaires, physiological assessment) were.
Wisconsin Upper Respiratory Symptom Survey (WURSS)Baseline (non-stress mid point of semester), 1-3 days into active beetroot shots (during final examination period), 4-6 days into active beetroot shots (during final examination period), 1-3 days after finishing beetroot shots (after final examinations)Assess symptoms of acute upper respiratory tract infections (common cold symptoms) by questionnaire
Adherence monitoring (feasibility)Every day during active beetroot shots (Days 1-7)Participants will upload a cell phone video of their intake for that day to a secure cloud folder, time stamp in comparison to assigned intake windows provides measure of adherence
Exhaled Nitric OxideBaseline (non-stress mid point of semester), 1-3 days into active beetroot shots (during final examination period), 4-6 days into active beetroot shots (during final examination period)The Fraction of NO in Exhaled Breath (FENO, in ppb) will be measured with an electrochemical gas analyzer (NIOX vero).
Viral Polymerase Chain ReactionBaseline (non-stress mid point of semester), 4-6 days into active beetroot shots (during final examination period)Binary positive/negative test results for a panel of viral and bacterial respiratory pathogens.

Secondary

MeasureTime frameDescription
MoodBaseline (non-stress mid point of semester), 4-6 days into active beetroot shots (during final examination period)Hospital Anxiety and Depression Scale (HADS)
Acute stressBaseline (non-stress mid point of semester), 1-3 days into active beetroot shots (during final examination period), 4-6 days into active beetroot shots (during final examination period), 1-3 days after finishing beetroot shots (after final examinations)Ad-hoc acute stress rating
CortisolBaseline (non-stress mid point of semester), 1-3 days into active beetroot shots (during final examination period), 4-6 days into active beetroot shots (during final examination period)Cortisol, from saliva sampled with passive drool test
Perceived stressBaseline (non-stress mid point of semester), 4-6 days into active beetroot shots (during final examination period)Perceived Stress Scale (PSS)
Blood pressure (systolic and diastolic blood pressure) and heart rateBaseline (non-stress mid point of semester), 1-3 days into active beetroot shots (during final examination period), 4-6 days into active beetroot shots (during final examination period)Measured after at least 10 min of acclimatization to the laboratory

Other

MeasureTime frameDescription
One-day Food RecordBaseline (non-stress mid point of semester), 1-3 days into active beetroot shots (during final examination period), 4-6 days into active beetroot shots (during final examination period)One-day food record via the Automated Self-Administered 24-Hour platform; control variable
Asymmetric dimethylarginineBaseline (non-stress mid point of semester), 1-3 days into active beetroot shots (during final examination period), 4-6 days into active beetroot shots (during final examination period)From Exhaled breath condensate or saliva, competitors/inhibitor of NO; exploratory mediator of FENO
ArginaseBaseline (non-stress mid point of semester), 1-3 days into active beetroot shots (during final examination period), 4-6 days into active beetroot shots (during final examination period)From Exhaled breath condensate or saliva, competitors/inhibitor of NO; exploratory mediator of FENO

Countries

United States

Contacts

Primary ContactSavannah Springfield, BA
sspringfield@mail.smu.edu(214) 768-6441
Backup ContactDanielle Young, Ph.D.
Danielle_Young@baylor.edu(254) 710-2236

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026